Your session is about to expire
← Back to Search
ICP-192 for Solid Tumors
Study Summary
This trial is testing a new cancer drug, ICP-192, on patients with advanced solid tumors and FGFR gene alterations. The trial has two parts, with the first part testing different doses of the drug to see what is safe and effective, and the second part expanding the study to more patients.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am 18 years old or older.I have major issues with my digestive system.I have had an organ or stem cell transplant.I have been treated with FGFR-targeting drugs, but not those specific to FGFR4.I do not have active hepatitis B, hepatitis C, or HIV.My organs are functioning well.I am fully active or can carry out light work.I am not pregnant or breastfeeding and willing to use contraception during and after the study.My cancer is advanced, cannot be surgically removed, and has not responded to standard treatments.The investigator believes that you have other conditions that make it unsuitable for you to participate in this study.My tests show a change in my FGFR gene.I have eye conditions that could worsen with treatment.My cancer has spread to my brain.I am still experiencing side effects from my previous cancer treatment.My cancer has returned or worsened after first-line chemotherapy.I have heart problems that are not well-managed.My phosphate levels are high despite treatment.You are expected to live for at least 3 more months.
- Group 1: ICP-192
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many medical facilities are actively engaging in this experiment?
"Five different medical centres are participating in this trial, including Mid Florida Hematology and Oncology located in Orange City, The Ohio State University based out of Columbus, and Arizona Oncology situated in Tucson."
How many individuals have registered for participation in the research?
"Correct. The official listing on clinicaltrials.gov states that this medical experiment, which was first uploaded on February 1st 2021, is currently seeking participants. Approximately 45 recruits need to be sourced from 5 different facilities."
Are there still opportunities for individuals to participate in this experiment?
"Correct. The clinicaltrials.gov database confirms that this research trial, which was initially published on February 1st 2021, is actively recruiting patients for participation. A total of 45 participants need to be sourced from 5 different medical sites."
What are the prime goals that this trial is attempting to achieve?
"The primary outcome of this long-term trial, which is estimated to run for up to three years, will be the incidence of treatment-related adverse effects. Additionally, phase I: dose escalation peak concentration (Cmax), phase II: dose expansion overall survival (OS) and progression free survival (PFS) will also be evaluated."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger